Technical Analysis for SNPX - Synaptogenix, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -1.92% | |
Lower Bollinger Band Walk | Weakness | -1.92% | |
Inside Day | Range Contraction | -1.92% | |
Wide Bands | Range Expansion | -1.92% | |
Gapped Up | Strength | -1.92% | |
Oversold Stochastic | Weakness | -1.92% | |
Stochastic Buy Signal | Bullish | 7.88% | |
Lower Bollinger Band Walk | Weakness | 7.88% | |
Outside Day | Range Expansion | 7.88% | |
Wide Bands | Range Expansion | 7.88% |
Alert | Time |
---|---|
Possible NR7 | 9 minutes ago |
Possible Inside Day | 9 minutes ago |
Down 1% | about 3 hours ago |
Rose Above Lower Bollinger Band | 1 day ago |
Up 5% | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 02/28/2024
Synaptogenix, Inc. Description
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated Bryostatin's regenerative mechanisms of action for the rare disease, Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Neuroscience Rare Diseases Alzheimer's Disease Neurodegenerative Diseases Multiple Sclerosis Stroke Amyotrophic Lateral Sclerosis Neurodegeneration Neurodegenerative Disorders Fragile X Syndrome Traumatic Brain Injury
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.775 |
52 Week Low | 2.32 |
Average Volume | 23,406 |
200-Day Moving Average | 4.05 |
50-Day Moving Average | 3.01 |
20-Day Moving Average | 2.89 |
10-Day Moving Average | 2.75 |
Average True Range | 0.24 |
RSI (14) | 43.18 |
ADX | 16.43 |
+DI | 20.22 |
-DI | 22.68 |
Chandelier Exit (Long, 3 ATRs) | 2.81 |
Chandelier Exit (Short, 3 ATRs) | 3.04 |
Upper Bollinger Bands | 3.39 |
Lower Bollinger Band | 2.39 |
Percent B (%b) | 0.26 |
BandWidth | 34.49 |
MACD Line | -0.16 |
MACD Signal Line | -0.11 |
MACD Histogram | -0.0466 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.93 | ||||
Resistance 3 (R3) | 2.90 | 2.77 | 2.88 | ||
Resistance 2 (R2) | 2.77 | 2.70 | 2.79 | 2.87 | |
Resistance 1 (R1) | 2.71 | 2.66 | 2.74 | 2.74 | 2.85 |
Pivot Point | 2.59 | 2.59 | 2.60 | 2.60 | 2.59 |
Support 1 (S1) | 2.53 | 2.52 | 2.56 | 2.56 | 2.45 |
Support 2 (S2) | 2.40 | 2.48 | 2.42 | 2.44 | |
Support 3 (S3) | 2.34 | 2.40 | 2.42 | ||
Support 4 (S4) | 2.37 |